Understand the source comparison
Best Peptides for Recurring Infections: Clinical Evidence Comparison
Thymosin Alpha-1 TLR2 agonist; enhances Th1 differentiation and Treg balance 1.6mg SC twice weekly × 8-12 weeks Randomized trials in immunocompromised cohorts (HIV, chemotherapy-induced neutropenia) 40-60% reduction in infection episodes 2-8°C; lyophilized sta
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- TLR2 agonist; enhances Th1 differentiation and Treg balance
- 1.6mg SC twice weekly × 8-12 weeks
- Randomized trials in immunocompromised cohorts (HIV, chemotherapy-induced neutropenia)
- 40-60% reduction in infection episodes
- 2-8°C; lyophilized stable 24 months at -20°C
- LL-37 (Cathelicidin)
- Direct membrane disruption; biofilm penetration; FPRL1-mediated anti-inflammatory signaling
- 5-20 mcg/mL topical; 0.5-2mg SC for systemic models
- In vitro bactericidal assays; chronic wound infection models
- 70-85% reduction in bacterial colonization (topical); 30-40% systemic
- 2-8°C; reconstituted solutions stable 7 days
- Thymalin
- Polypeptide thymic extract; restores thymulin and thymopoietin signaling; zinc-dependent T-cell maturation
- 10mg IM daily × 10 days, quarterly cycles
- Russian Federation clinical trials in elderly respiratory infection cohorts
- 50% reduction in annual infection frequency
- 2-8°C; unreconstituted lyophilized stable 18 months
- KPV (Lysine-Proline-Valine)
- α-MSH-derived tripeptide; inhibits NF-κB and reduces inflammatory cytokine production
- 500 mcg-2mg SC daily × 4-8 weeks
- Murine IBD models; limited human data in chronic inflammatory conditions
- Indirect effect. Reduces infection susceptibility by resolving inflammatory barrier dysfunction
- 2-8°C; stable 12 months lyophilized